Plain-English translation of NCT06807424 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help people with psoriatic arthritis—a condition that causes joint pain, swelling, and skin rashes. Researchers want to know if this medication works better than a placebo (a dummy pill with no active drug) at reducing joint symptoms and skin symptoms. Some participants may have already tried other arthritis medications, while others will be trying a treatment for the first time.
Psoriatic arthritis can be painful and disabling, and not all patients respond well to current treatments. This trial is testing whether this new medication could offer another option for people whose arthritis is still active despite trying other treatments.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication at one of two doses, or a placebo. If you receive the placebo, you will switch to one of the medication doses after 16 weeks. You will visit the study clinic at regular intervals for check-ups, blood tests, and assessments of your joint and skin symptoms. If the treatment is working well for you and you wish to continue, you may be able to join an extended study where you keep taking the medication for a longer period.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States